Merck notches 38th approval for Keytruda, seventh indication for gastrointestinal cancer

The FDA on Thurs­day ap­proved Mer­ck’s an­ti-PD-1 ther­a­py to treat a type of gas­troin­testi­nal can­cer in com­bi­na­tion with chemother­a­py, mark­ing the drug’s 38th in­di­ca­tion.

The ap­proval is to treat lo­cal­ly ad­vanced un­re­sectable or metasta­t­ic HER2-neg­a­tive gas­tric or gas­troe­sophageal junc­tion ade­no­car­ci­no­ma when used in com­bi­na­tion with flu­o­ropy­rim­i­dine- and plat­inum-con­tain­ing chemother­a­py. It marks the drug’s sev­enth in­di­ca­tion for gas­troin­testi­nal can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.